المؤلفون: GwangPyo Ko, Won Kim, Seoyeon Park, Bon Jeong Ku, Sae Kyung Joo, Hyun Ju You, Jiyeon Si, Giljae Lee, Dong Hyeon Lee

المصدر: Computational and Structural Biotechnology Journal, Vol 19, Iss, Pp 5920-5930 (2021)
Computational and Structural Biotechnology Journal

مصطلحات موضوعية: endocrine system diseases, BMI, body mass index, Disease, Gut flora, Biochemistry, Gastroenterology, Structural Biology, LDL, low-density lipoprotein, Enterotype, biology, NASH-CRN, non-alcoholic steatohepatitis clinical research network, Fatty liver, Computer Science Applications, Cohort, LPS, lipopolysaccharide, Research Article, PICRUSt2, phylogenetic investigation of communities by reconstruction of unobserved states 2, Biotechnology, NAFLD, non-alcoholic fatty liver disease, medicine.medical_specialty, FDR, false discovery rate, NASH, non-alcoholic steatohepatitis, Biophysics, HbA1c, glycosylated hemoglobin, digestive system, MaAsLin2, microbiome multivariable association with linear models 2, Non-alcoholic fatty liver disease (NAFLD), ALT, alanine aminotransferase, Diabetes mellitus, Internal medicine, T2D, type 2 diabetes mellitus, Type 2 diabetes mellitus, Genetics, medicine, NAFL, non-alcoholic fatty liver, Microbiome, FBS, fasting blood sugar, ComputingMethodologies_COMPUTERGRAPHICS, Gut microbiome, business.industry, Type 2 Diabetes Mellitus, nutritional and metabolic diseases, Biomarker, medicine.disease, biology.organism_classification, digestive system diseases, business, FLI, fatty liver index, TP248.13-248.65

الوصف: Graphical abstract
Non-alcoholic fatty liver disease (NAFLD) is closely associated with type 2 diabetes mellitus (T2D), and these two metabolic diseases demonstrate bidirectional influences. The identification of microbiome profiles that are specific to liver injury or impaired glucose metabolism may assist understanding of the role of the gut microbiota in the relationship between NAFLD and T2D. Here, we studied a biopsy-proven Asian NAFLD cohort (n = 329; 187 participants with NAFLD, 101 with NAFLD and T2D, and 41 with neither) and identified Enterobacter, Romboutsia, and Clostridium sensu stricto as the principal taxa associated with the severity of NAFLD and T2D, whereas Ruminococcus and Megamonas were specific to NAFLD. In particular, the taxa that were associated with both severe liver pathology and T2D were also significantly associated with markers of diabetes, such as fasting blood glucose and Hb1Ac. Enterotype analysis demonstrated that participants with NAFLD had a significantly higher proportion of Bacteroides and a lower proportion of Ruminococcus than a Korean healthy twin cohort (n = 756). However, T2D could not be clearly distinguished from NAFLD. Analysis of an independent T2D cohort (n = 185) permitted us to validate the T2D-specific bacterial signature identified in the NAFLD cohort. Functional inference analysis revealed that endotoxin biosynthesis pathways were significantly enriched in participants with NAFLD and T2D, compared with those with NAFLD alone. These findings may assist with the development of effective therapeutic approaches for metabolic diseases that are associated with specific bacterial signatures.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f954c67889fd6d23e7de29c2b7336727Test
http://www.sciencedirect.com/science/article/pii/S2001037021004542Test

المؤلفون: Lucia Parlati, Catherine Postic, Marion Régnier, Hervé Guillou

المساهمون: LESUR, Hélène, Impact du métabolisme des acides gras des tissus adipeux et du foie sur l'insulinorésistance - - HepAdialogue2017 - ANR-17-CE14-0015 - AAPG2017 - VALID, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Catholique de Louvain = Catholic University of Louvain (UCL), ToxAlim (ToxAlim), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Ecole d'Ingénieurs de Purpan (INPT - EI Purpan), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Toxicologie Intégrative & Métabolisme (ToxAlim-TIM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Toulouse III - Paul Sabatier (UT3), Lucia Parlati and Catherine Postic received funding from the French association for the study of the liver (AFEF). Catherine Postic and Herve Guillou received funding from the Agence Nationale de la Recherche (ANR-17-CE14-0015Hepadialogue)., ANR-17-CE14-0015,HepAdialogue,Impact du métabolisme des acides gras des tissus adipeux et du foie sur l'insulinorésistance(2017), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)

المصدر: JHEP Reports
JHEP Reports Innovation in Hepatology
JHEP Reports Innovation in Hepatology, 2021, 3 (6), pp.100346. ⟨10.1016/j.jhepr.2021.100346⟩
JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (6), pp.100346. ⟨10.1016/j.jhepr.2021.100346⟩

مصطلحات موضوعية: HFD, high-fat diet, SREBP-1c, [SDV]Life Sciences [q-bio], Disease, Review, ACC, acetyl-CoA carboxylase, ASK1, apoptosis signal-regulating kinase 1, Chronic liver disease, Bioinformatics, ChREBP, carbohydrate responsive element–binding protein, PPARα, NEFA, TNF-α, tumour necrosis factor-α, 0302 clinical medicine, Fibrosis, Immunology and Allergy, Medicine, IL-, interleukin, VLDL, very low-density lipoprotein, 0303 health sciences, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, NEFA, non-esterified fatty acid, Fatty liver, Gastroenterology, NASH, lipotoxicity, FAS, fatty acid synthase, animal models, 3. Good health, [SDV] Life Sciences [q-bio], PY, persons/years, Lipotoxicity, FXR, Saturated fatty acid, JNK, c-Jun N-terminal kinase, 030211 gastroenterology & hepatology, LXR, CAP, controlled attenuation parameter, HSL, hormone-sensitive lipase, HSC, hepatic stellate cells, GGT, gamma glutamyltransferase, NAFLD, non-alcoholic fatty liver disease, ChREBP, NASH, non-alcoholic steatohepatitis, SFA, saturated fatty acid, TCA, tricarboxylic acid, Phf2, histone demethylase plant homeodomain finger 2, digestive system, 03 medical and health sciences, glucotoxicity, FXR, farnesoid X receptor, NAFLD, FFA, free fatty acid, Internal Medicine, RCT, randomised controlled trial, Liver X receptor, PPARa, 030304 developmental biology, FGF21, fibroblast growth factor-21, MCD, methionine- and choline-deficient, HVPG, hepatic venous pressure gradient, Hepatology, business.industry, PUFAs, polyunsaturated fatty acids, nutritional and metabolic diseases, TLR4, Toll-like receptor 4, SCD1, stearoyl-CoA desaturase-1, medicine.disease, digestive system diseases, PPARα, peroxisome proliferator-activated receptor-α, SREBP-1c, sterol regulatory element–binding protein-1c, Steatosis, LXR, liver X receptor, business, HCC, hepatocellular carcinoma, MUFA, monounsaturated fatty acids, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

الوصف: International audience; Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD. In this review, we will provide an update on the known molecular pathways involved in the pathophysiology of NAFLD and on ongoing studies of new therapeutic targets.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba31673956635c337dc60791ff712432Test
https://pubmed.ncbi.nlm.nih.gov/34667947Test

المؤلفون: Manuel Romero-Gómez, Patrizia Carrieri, Mattias Ekstedt, Shira Zelber-Sagi, Katja Novak, Vlad Ratziu, Quentin M. Anstee, Frank Tacke, Adam Palayew, Jeffrey V. Lazarus, Helena Cortez-Pinto, Giulio Marchesini

المساهمون: Instituto de Salud Global - Institute For Global Health [Barcelona] (ISGlobal), University of Barcelona, McGill University = Université McGill [Montréal, Canada], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Linköping University (LIU), Alma Mater Studiorum University of Bologna (UNIBO), Istituto di ricovero e cura a carattere scientifico Azienda Ospedaliera Universitaria 'San Martino' (IRCCS AOU San Martino), University Medical Centre Ljubljana [Ljubljana, Slovenia] (UMCL), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Liver Unit, Clínica Universitaria, CIBER-EHD, Hospital Universitario Virgen del Rocío [Sevilla], Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Haifa [Haifa], Universidade de Lisboa (ULISBOA), Newcastle University [Newcastle], Lazarus J.V., Palayew A., Carrieri P., Ekstedt M., Marchesini G., Novak K., Ratziu V., Romero-Gomez M., Tacke F., Zelber-Sagi S., Cortez-Pinto H., Anstee Q.M., EASL International Liver Foundation, Gilead Sciences, Allergan Foundation, Bristol-Myers Squibb, Pfizer, Resoundant, Intercept Pharmaceuticals, Genfit, Ministerio de Ciencia, Innovación y Universidades (España), Instituto de Salud Carlos III, European Commission, Generalitat de Catalunya, NIHR Biomedical Research Centre (UK), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Universidade de Lisboa = University of Lisbon (ULISBOA), Repositório da Universidade de Lisboa, Gestionnaire, Hal Sorbonne Université

المصدر: JHEP Reports Innovation in Hepatology
JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (2), pp.100234. ⟨10.1016/j.jhepr.2021.100234⟩
Digital.CSIC. Repositorio Institucional del CSIC
instname
JHEP Reports
JHEP Reports, Vol 3, Iss 2, Pp 100234-(2021)

مصطلحات موضوعية: ESPEN, type 2 diabetes mellitus, EASL, European Association for the Study of the Liver, [SDV]Life Sciences [q-bio], Disease, Multiple joint correspondence analysi, WHO, 0302 clinical medicine, Non-alcoholic fatty liver disease, Liver health, Multiple joint correspondence analysis, Policy preparedness, Health policy, Metabolic-associated fatty liver disease, Non-alcoholic steatohepatitis, Europe, Multidisciplinary approach, EASD, European Association for the Study of Diabetes, European Association for the Study of Diabetes, Epidemiology, Immunology and Allergy, Medicine, European Association for the Study of Obesity, European Society of Clinical Nutrition and Metabolism, EEA, EASO, European Association for the Study of Obesity, media_common, Gastroenterology, NASH, food and beverages, ESPEN, European Society of Clinical Nutrition and Metabolism, 3. Good health, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, Preparedness, 030211 gastroenterology & hepatology, Research Article, European Association for the Study of the Liver, EEA, European Economic Area, medicine.medical_specialty, NAFLD, non-alcoholic fatty liver disease, EASD, NASH, non-alcoholic steatohepatitis, multiple correspondence analysis, T2DM, Gastroenterology and Hepatology, EASL, World Health Organization, digestive system, WHO, World Health Organization, European Economic Area, 03 medical and health sciences, Environmental health, EU, European Union, NAFLD, Gastroenterologi, Internal Medicine, media_common.cataloged_instance, European Union, lcsh:RC799-869, European union, MCA, multiple correspondence analysis, Hepatology, business.industry, Public health, MCA, nutritional and metabolic diseases, non-alcoholic fatty liver disease, T2DM, type 2 diabetes mellitus, medicine.disease, Obesity, digestive system diseases, EASO, lcsh:Diseases of the digestive system. Gastroenterology, business, EU, Non-alcoholic steatohepatiti

الوصف: [Background & Aims] Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent emerging condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to ensure that health systems can deliver effective care. We present a NAFLD Preparedness Index for Europe.
[Methods] In June 2019, data were extracted by expert groups from 29 countries to complete a 41-item questionnaire about NAFLD. Questions were classified into 4 categories: policies/civil society (9 questions), guidelines (16 questions), epidemiology (4 questions), and care management (12 questions). Based on the responses, national preparedness for each indicator was classified into low, middle, or high-levels. We then applied a multiple correspondence analysis to obtain a standardised preparedness score for each country ranging from 0 to 100.
[Results] The analysis estimated a summary factor that explained 71.3% of the variation in the dataset. No countries were found to have yet attained a high-level of preparedness. Currently, the UK (75.5) scored best, although falling within the mid-level preparedness band, followed by Spain (56.2), and Denmark (43.4), whereas Luxembourg and Ireland were the lowest scoring countries with a score of 4.9. Only Spain scored highly in the epidemiology indicator category, whereas the UK was the only country that scored highly for care management.
[Conclusions] The NAFLD Preparedness Index indicates substantial variation between countries’ readiness to address NAFLD. Notably, even those countries that score relatively highly exhibit deficiencies in key domains, suggesting that structural changes are needed to optimise NAFLD management and ensure effective public health approaches are in place.
[Lay summary] Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures aimed at preventing disease while also ensuring that health systems can deliver effective care to affected populations. This study defined preparedness as having adequate policies and civil society engagement, guidelines, epidemiology, and care management. NAFLD preparedness was found to be deficient in all 29 countries studied, with great variation among the countries and the 4 categories studied.
The original data collection was funded by the EASL International Liver Foundation with support from Gilead Sciences Europe Ltd., Allergan Pharmaceutical International Ltd., Bristol-Myers-Squibb Company, Pfizer Inc., and Resoundant Inc. The statistical analysis was funded by the EASL International Liver Foundation with support from Bristol-Myers-Squibb Company, Intercept, and Genfit. JVL is supported by a Spanish Ministry of Science, Innovation and Universities Miguel Servet grant (Instituto de Salud Carlos III/ESF, European Union [CP18/00074]) and further acknowledges institutional support from the Spanish Ministry of Science, Innovation and Universities through the ‘Centro de Excelencia Severo Ochoa 2019–2023’ Programme (CEX2018-000806-S), and support from the Government of Catalonia through the CERCA Programme. QMA and VR are members of the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413. QMA, VR, HCP, ME, and MRG are members of the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the IMI2 Program of the European Union under Grant Agreement 777377. QMA is a Newcastle NIHR Biomedical Research Centre investigator. AP, PC, GM, KN, FT, and SZS have no financial support statements to disclose.
With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2018-000806-S).

وصف الملف: ELETTRONICO; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::237265ca3a905978c88b2731dd069191Test
https://hal.sorbonne-universite.fr/hal-03174867Test

المؤلفون: Linda Henry, Zobair M. Younossi

المصدر: JHEP Reports

مصطلحات موضوعية: medicine.medical_specialty, NAFLD, non-alcoholic fatty liver disease, Cirrhosis, STAT3, signal transducer and activator of transcription 3, NASH, non-alcoholic steatohepatitis, Context (language use), Disease, Type 2 diabetes, Review, CVD, cardiovascular disease, Gastroenterology, digestive system, ELF, enhanced liver fibrosis, PDGF, platelet-derived growth factor, Internal medicine, Epidemiology, Internal Medicine, Immunology and Allergy, Medicine, awareness, FIB-4, fibrosis-4, ALD, alcohol-related liver disease, neoplasms, Hepatology, business.industry, cirrhosis, Fatty liver, nutritional and metabolic diseases, non-cirrhosis, medicine.disease, Obesity, VEGF, vascular endothelial growth factor, digestive system diseases, natural history, Hepatocellular carcinoma, surveillance, business, HCC, hepatocellular carcinoma, TNF, tumour necrosis factor-α

الوصف: Summary The prevalence of hepatocellular carcinoma (HCC) is increasing worldwide, whereas that of most other cancers is decreasing. Non-alcoholic fatty liver disease (NAFLD), which has increased with the epidemics of obesity and type 2 diabetes, increases the risk of HCC. Interestingly, NAFLD-associated HCC can develop in patients with or without cirrhosis. A lack of awareness about NAFLD-related HCC has led to delays in diagnosis. Therefore, a large number of patients with HCC are diagnosed with advanced-stage HCC with low 5-year survival. In this context, increasing awareness of NAFLD and NAFLD-related HCC may lead to earlier diagnosis and more effective interventions.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48a4964dc0d86470071e38394d6df7fbTest
https://pubmed.ncbi.nlm.nih.gov/34189448Test

المؤلفون: Syed Tasleem, Umar Hayat, Saba Afroz, Ahmed Haris, Hayrettin Okut, Ali A. Siddiqui

المصدر: Annals of Hepatology, Vol 20, Iss, Pp 100254-(2021)

مصطلحات موضوعية: Liver Cirrhosis, medicine.medical_specialty, Specialties of internal medicine, Drinking Behavior, Disease, Chronic liver disease, Gastroenterology, NAFLD (non-alcoholic fatty liver disease), Coffee, NASH (Non-alcoholic steatohepatitis), 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Internal medicine, Caffeine, Epidemiology, medicine, Humans, Hepatology, business.industry, Fatty liver, Confidence interval, nutritional and metabolic diseases, General Medicine, medicine.disease, digestive system diseases, Relative risk, chemistry, RC581-951, 030220 oncology & carcinogenesis, Meta-analysis, 030211 gastroenterology & hepatology, business

الوصف: Introduction and objectives Non-alcoholic fatty liver disease (NAFLD) is a widespread chronic liver disease. It is considered a multifactorial disorder that can progress to liver fibrosis and cause a worldwide public health concern. Coffee consumption may have a protective impact on NAFLD and liver fibrosis. However, the evidence from the previous studies is inconsistent. This meta-analysis summarizes available literature. Materials and methods This study comprises two meta-analyses. The first meta-analysis summarizes the effect of coffee consumption on NAFLD in those who did or did not drink coffee. The second analysis compares the risk of liver fibrosis development between NAFLD patients who did or did not drink coffee. Pooled risk ratios (RR) and confidence intervals (CI) of observational studies were estimated. Results Of the total collected 321 articles, 11 met our eligibility criteria to be included in the analysis. The risk of NAFLD among those who drank coffee compared to those who did not was significantly lower with a pooled RR value of 0.77 (95% CI 0.60–0.98). Moreover, we also found a significantly reduced risk of liver fibrosis in those who drink coffee than those who did not drink in the NAFLD patients with the relative risk (RR) of 0.68 (95% CI 0.68–0.79). Conclusions Regular coffee consumption is significantly associated with a reduced risk of NAFLD. It is also significantly associated with decreased risk of liver fibrosis development in already diagnosed NAFLD patients. Although coffee consumption may be considered an essential preventive measure for NAFLD, this subject needs further epidemiological studies.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db1203a30b676744792d706528112a5Test
https://pubmed.ncbi.nlm.nih.gov/32920163Test

المؤلفون: Nikolaos Perakakis, Konstantinos Stefanakis, Christos S. Mantzoros

المصدر: Metabolism

مصطلحات موضوعية: Proteomics, HCC, Hepatocellular carcinoma, Cirrhosis, SWE, Shear wave elastography, Endocrinology, Diabetes and Metabolism, TM6SF2, Transmembrane 6 superfamily member 2, Disease, CK-18, Cytokeratin-18, GCKR, Glucokinase regulatory protein, HDACis, HDAC inhibitors, transcriptomics, HSI, Hepatic Steatosis index, 0302 clinical medicine, Endocrinology, DAG, Diacylglycerol, EPA, Eicosapentanoic acid, MRI-PDFF, Magnetic resonance imaging derived proton density fat fraction, PE, Phosphatidylethanolamine, lncRNA, Long noncoding RNA, CAP, Controlled attenuation parameter, IgG, Immunoglobulin G, NASH, NAFLD, Non-alcoholic fatty liver disease, Genomics, TGF, Transforming growth factor, DHA, Docosahexaenoic acid, GRS, Genetic risk score, CRP, C-reactive protein, DHEA, Dehydroepiandrosterone, DNMTis, DNA methylation inhibitors, medicine.medical_specialty, PDGF, Platelet-derived growth factor, NASH, non-alcoholic steatohepatitis, DZNep, 3-deazaneplanocin A, tRNA, Transport RNA, PLA2, Phospholipase A2, digestive system, Article, TG, Triglyceride, 03 medical and health sciences, IL-32, Interleukin 32, AUROC, Area under the receiver operator characteristics, Humans, Metabolomics, MS, Mass Spectrometry, SPM, Specialized pro-resolving mediator, nutritional and metabolic diseases, TOF, Time-of-flight, medicine.disease, Omics, AST, Aspartate transaminase, PNPLA3, Patatin-like phospholipase domain-containing-3, digestive system diseases, NAFL, Non-alcoholic fatty liver, 030104 developmental biology, FXR, Farnesoid X receptor, PTPRE, protein-tyrosine phosphatase epsilon, Steatohepatitis, IGF, Insulin growth factor, ROS, Reactive oxygen species, ACC, Acetyl-coA carboxylase, Liver Cirrhosis, 0301 basic medicine, F#, Fibrosis (score), LPE, Lysophosphatidylethanolamine, LSM, Liver stiffness measurement, IL-32, Interleukin-32, VCTE, Vibration-controlled transient elastography, Bioinformatics, glycomics, HAT, Histone acetyltransferase, Non-alcoholic Fatty Liver Disease, APRI, Aspartate aminotransferase to platelet ratio index, steatosis, FADS, Fatty acid desaturase, circRNA, Circular RNA, NFS, NAFLD fibrosis score, PUFA, Polyunsaturated fatty acid, SNP, Single nucleotide polymorphism, NAS, NAFLD activity score, medicine.diagnostic_test, Fatty liver, AA, Arachidonic acid, IL-10, Interleukin-10, SFA, Saturated fatty acids, Liver biopsy, LPC, Lysophosphatidylcholine, FIB-4, Fibrosis-4 score, IGFBP, Insulin growth factor binding protein, ApoE, Apolipoprotein E, GGT, Gamma-glutamyltransferase, ChREBP, Carbohydrate, responsive element-binding protein, MUFA, Monounsaturated fatty acid, PC, Phosphatidylcholine, 030209 endocrinology & metabolism, PPAR, Peroxisome proliferator-activated receptor, HFD, High fat diet, Internal medicine, medicine, Animals, MetS, Metabolic syndrome, IL-6, Interleukin-6, MRE, magnetic resonance elastography, SIRT, Sirtuin, SELDI, Surface-enhanced laser desorption/ionization, BMI, Body mas index, business.industry, HDAC, Histone deacetylase, WC, Waist circumference, ALT, Alanine aminotransferase, CHI3L1, Chitinase 3 Like 1, FFA, Free fatty acids, GWAS, Genome - wide association studies, epigenomics, HSD17B13, 17-b retinol dehydrogenase 13, miR, Micro RNA, lipidomics, 1H-MRS, Magnetic resonance imaging and proton spectroscopy, MBOAT7, Membrane bound O-acyltransferase domain-containing 7, Steatosis, business, OR, Odds ratio, T2DM, Type 2 Diabetes Mellitus

الوصف: Non-alcoholic fatty liver disease (NAFLD) is a multifaceted metabolic disorder, whose spectrum covers clinical, histological and pathophysiological developments ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and liver fibrosis, potentially evolving into cirrhosis, hepatocellular carcinoma and liver failure. Liver biopsy remains the gold standard for diagnosing NAFLD, while there are no specific treatments. An ever-increasing number of high-throughput Omics investigations on the molecular pathobiology of NAFLD at the cellular, tissue and system levels produce comprehensive biochemical patient snapshots. In the clinical setting, these applications are considerably enhancing our efforts toward obtaining a holistic insight on NAFLD pathophysiology. Omics are also generating non-invasive diagnostic modalities for the distinct stages of NAFLD, that remain though to be validated in multiple, large, heterogenous and independent cohorts, both cross-sectionally as well as prospectively. Finally, they aid in developing novel therapies. By tracing the flow of information from genomics to epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and glycomics, the chief contributions of these techniques in understanding, diagnosing and treating NAFLD are summarized herein.
Highlights • Numerous non-invasive NAFLD biomarkers are developed but none is broadly applicable • OMICS enrich the understanding, diagnosis and treatment of NAFLD, NASH and fibrosis • Genomics and epigenomics pinpoint NAFLD polymorphisms and DNA methylation loci • Transcriptomics and proteomics prove the diagnostic value of miRNAs and peptides • Metabolomics, lipidomics and glycomics offer robust panels and therapeutic insight

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29bb96bcd7fb056ebf01eec2214ad114Test
https://doi.org/10.1016/j.metabol.2020.154320Test

المؤلفون: Yemi Oluboyede, Gulnar Fattakhova, Lorraine McSweeney, Luke Vale, Lynda C. Doward, Fiona Beyer, Clifford A. Brass, Quentin M. Anstee, Matthew Breckons, Laura Ternent, Maria-Magdalena Balp, Arun J. Sanyal

المصدر: JHEP Reports
JHEP Reports, Vol 2, Iss 3, Pp-(2020)

مصطلحات موضوعية: medicine.medical_treatment, Disease, Liver disease, 0302 clinical medicine, Immunology and Allergy, 030212 general & internal medicine, Non-alcoholic steatohepatitis, education.field_of_study, Gastroenterology, PRO, patient-reported outcome, LDSI, liver disease symptom index, 3. Good health, health-related quality of life, Cirrhosis, 030211 gastroenterology & hepatology, Patient-reported outcome, SF-36, short form health profile 36, Research Article, FDA, United States Food and Drug Administration, RI, researcher interpretation, HRQoL, health-related quality of life, NAFLD, non-alcoholic fatty liver disease, medicine.medical_specialty, SF-36, NASH, non-alcoholic steatohepatitis, Population, liver, digestive system, Support group, MS, multiple sclerosis, 03 medical and health sciences, Quality of life (healthcare), NAFLD, PHAQ, patient-reported outcome measurement information system health assessment questionnaire, Internal Medicine, medicine, NAFL, non-alcoholic fatty liver, CLDQ, chronic liver disease questionnaire, lcsh:RC799-869, Intensive care medicine, education, patient-reported outcome measures, Hepatology, business.industry, nutritional and metabolic diseases, medicine.disease, QoL, quality of life, Mental health, digestive system diseases, FIS, fatigue impact scale, PROM, patient-reported outcome measure, EMA, European Medicines Agency, COSMIN, The COnsensus-based Standards for the selection of health Measurement INstruments, lcsh:Diseases of the digestive system. Gastroenterology, business, LDQoL, liver disease quality of life questionnaire

الوصف: Background & Aims Non-alcoholic steatohepatitis (NASH) is known to have a negative impact on patients' health-related quality of life (HRQoL), even before progression to cirrhosis has occurred. The burden of NASH-related cirrhosis from the patient perspective remains poorly understood. Herein, we aimed to identify the burden of disease and HRQoL impairment among patients with NASH-related compensated cirrhosis. Methods This targeted literature review sought first to identify the humanistic burden of disease from the perspective of patients with diagnosed NASH-cirrhosis and, secondly, to identify generic or disease-specific patient-reported outcome measures (PROMs) used to assess the impact of NASH-cirrhosis. Searches were conducted in bibliographical databases, grey or unpublished literature, liver disease websites, support group websites and online blogs. A quality assessment of specific PROMs was conducted. Results Patients with NASH-cirrhosis are reported to suffer from lower HRQoL than patients with non-cirrhotic NASH and the general population with respect to physical health/functioning, emotional health and worry, and mental health. Thirteen PROMs were identified, of which 4 were liver-disease specific: CLDQ, CLDQ-NAFLD, LDQoL and LDSI. The most commonly used measures do not comply with current industry or regulatory standards for PROMs and/or are not validated for use in a cirrhotic NASH population. Conclusions Patients with NASH-cirrhosis have lower HRQoL and poorer physical health than patients with non-cirrhotic NASH. However, the literature lacked detail of the everyday impact on patients' lives. Currently, a number of PROMs are available to measure the impact of the disease in patients with chronic liver conditions. The lack of studies that include qualitative insights in this population mandates further exploration and research. Lay summary It is not well understood how having non-alcoholic fatty liver disease (NAFLD)-related cirrhosis affects a person's everyday wellbeing and quality of life. Some research has been done with patients who have early stages of liver disease but not people with cirrhosis. We found that patients with NAFLD-related cirrhosis tended to have poorer health than patients without cirrhosis. But there was not very much information from patients themselves and there were no tools or questionnaires just for this group of patients.
Graphical abstract
Highlights • The burden of cirrhotic NASH from the patient perspective remains poorly understood. • Patients with NASH-related compensated cirrhosis are reported to suffer from lower HRQoL. • Most commonly used PROMs are not validated for use in a cirrhotic NASH population.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee751f2b6ffd99b10142118b951f0fcdTest
https://doi.org/10.1016/j.jhepr.2020.100099Test

المؤلفون: Muhammad Ibrahim, Maryam Abimbola Mikail, Idris Adewale Ahmed, Rozana Othman, Mohammad Rais Mustafa

المصدر: Saudi Journal of Biological Sciences, Vol 26, Iss 7, Pp 1519-1524 (2019)
Saudi Journal of Biological Sciences

مصطلحات موضوعية: 0106 biological sciences, 0301 basic medicine, medicine.medical_specialty, NAFLD, non-alcoholic fatty liver disease, Weight loss, Cirrhosis, NASH, non-alcoholic steatohepatitis, EASL, European Association for the Study of the Liver, DHA, docosahexaenoic acid, Disease, 01 natural sciences, Gastroenterology, digestive system, Article, 03 medical and health sciences, Liver disease, Internal medicine, EASD, European Association for the Study of Diabetes, medicine, DDT, dichlorodiphenyltrichloroethane, EASO, European Association for the Study of Obesity, Exercise, lcsh:QH301-705.5, business.industry, Fatty liver, nutritional and metabolic diseases, medicine.disease, EPA, eicosapentaenoic acid, Lifestyle, digestive system diseases, Diet, AASLD, American Association for the Study of Liver Diseases, 030104 developmental biology, lcsh:Biology (General), Hepatocellular carcinoma, ALA, alpha-linolenic acid, Steatosis, medicine.symptom, Steatohepatitis, General Agricultural and Biological Sciences, business, 010606 plant biology & botany

الوصف: Non-alcoholic fatty liver disease (NAFLD) is a multi-factorial disease and the most common of chronic liver diseases worldwide. The four clinical-pathological entities which are usually followed by NAFLD course include non-alcoholic steatosis, non-alcoholic steatohepatitis, advanced fibrosis/cirrhosis, and hepatocellular carcinoma. The cornerstones of NAFLD management and treatment, however, are healthy lifestyles such as dietary modifications, regular physical activity, and gradual weight loss. At present, no drugs or pharmacological agents have been approved for long-term treatment of NAFLD. Therefore, lifestyle modification is considered the main clinical recommendation and an initial step for the management of NAFLD. Keywords: Diet, Exercise, Lifestyle, Weight loss, Liver disease

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f2047a39f739379090519c0d5b90777Test
https://pubmed.ncbi.nlm.nih.gov/31762620Test

المؤلفون: George Boon-Bee Goh, Ruth Sargent, Srinivasan Dasarathy, Jaividhya Dasarathy, Aynur Unalp-Arida, Achuthan Sourianarayanane, Rish K. Pai, Arthur J. McCullough, Mangesh R. Pagadala, Carol Hawkins, Amer Khiyami, Lisa Yerian

المصدر: BBA Clinical

مصطلحات موضوعية: Very low-density lipoprotein, BMI, body mass index, LDL, low density lipoprotein cholesterol, INR, international normalised ratio, AST, aspartate aminotransferase, Disease, Gastroenterology, Fibrosis score, NFS, NAFLD fibrosis score, DM, type 2 diabetes mellitus, apoB-100, apolipoprotein B-100, NAS, NAFLD activity score, TGs, triglycerides, Fatty liver, Regular Article, Non-diabetic, ACE-I, angiotensin-converting enzyme-inhibitor, 3. Good health, ARB, angiotensin receptor blocker, Molecular Medicine, Non diabetic, NAFLD, non-alcoholic fatty liver disease, medicine.medical_specialty, NASH, non-alcoholic steatohepatitis, NASH CRN, Non-alcoholic Steatohepatitis Clinical Research Network, ORs, odd ratios, digestive system, VLDL, very-low-density lipoproteins, Pathology and Forensic Medicine, ER, endoplasmic reticulum, Diabetic, ALT, alanine aminotransferase, NAFLD, Physiology (medical), Diabetes mellitus, Internal medicine, medicine, FFAs, free-fatty acids, In patient, Chol, total cholesterol, ALP, alkaline phosphatase, business.industry, SDs, standard deviations, nutritional and metabolic diseases, Non alcoholic, NAFLD fibrosis score, medicine.disease, CIs, confidence intervals, digestive system diseases, HDL, high density lipoprotein cholesterol, Endocrinology, HOMA-IR, Homeostatic model assessment—insulin resistance, business

الوصف: Background While non-alcoholic fatty liver disease (NAFLD) has been well characterised in patients with diabetes mellitus (DM), less is known about NAFLD in non-DM patients. We investigated the clinical characteristics of NAFLD patients with and without DM and accuracy of the NAFLD fibrosis score (NFS) in these two NAFLD groups. Methods Clinical, biochemical and histological variables were evaluated in this prospective cross-sectional study of 503 patients with biopsy proven NAFLD. Comparisons between patients with and without DM were analysed. NFS was correlated with liver histology to assess its robustness in patients with and without DM. Results There were 503 biopsy proven NAFLD patients with 48% of the cohort being diabetic. Relative to patients without DM, patients with DM were older (52 vs. 46 years, p
Highlights • Patients with diabetes have more severe NAFLD based on histology. • Severe NAFLD can occur in a considerable proportion of non-diabetic NAFLD patients. • The NAFLD fibrosis score may be less accurate in non-diabetics.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a7eb9348140df9a8c541a554f5a132dTest

المؤلفون: Sonia García-Calzón, Karl Bacos, Cajsa Davegårdh, Charlotte Ling

المصدر: Molecular Metabolism
Molecular Metabolism, Vol 14, Iss, Pp 12-25 (2018)

مصطلحات موضوعية: 0301 basic medicine, HFD, high-fat diet, endocrine system diseases, BMI, body mass index, FH, family history, OXPHOS, oxidative phosphorylation, NBW, normal birth weight, Genome-wide association study, HDAC, histone deacetylase, Disease, Type 2 diabetes, Bioinformatics, WGBS, whole-genome bisulfite sequencing, CIT, causal inference test, 0302 clinical medicine, Special Section on Epigenetics (2018), PUFA, polyunsaturated fatty acids, DNA methylation, ncRNA, non-coding RNA, DMR, differentially methylated region, SNP, single nucleotide polymorphism, MZ, monozygotic, 3. Good health, Adipose Tissue, Liver, eQTL, expression quantitative trait loci, Medical genetics, Epigenetics, nt, nucleotide, lcsh:Internal medicine, medicine.medical_specialty, NAFLD, non-alcoholic fatty liver disease, HOMA-IR, homeostatic model assessment for insulin resistance, NASH, non-alcoholic steatohepatitis, HDL, high-density lipoprotein, 030209 endocrinology & metabolism, T2D, type 2 diabetes, Biology, EWAS, epigenome-wide association study, LBW, low birth weight, 03 medical and health sciences, Islets of Langerhans, Insulin resistance, medicine, OGTT, oral glucose-tolerance test, Humans, lcsh:RC31-1245, Muscle, Skeletal, GWAS, genome-wide association study, Molecular Biology, nutritional and metabolic diseases, Cell Biology, Epigenome, medicine.disease, mQTL, methylation quantitative trait loci, 030104 developmental biology, Diabetes Mellitus, Type 2, DNMT, DNA methyltransferase, SFA, saturated fatty acids, TSS, transcription start site, MeDIP, methylated DNA immunoprecipitation, HbA1c, glycated hemoglobin A1c

الوصف: Background: Type 2 diabetes (T2D) is a multifactorial, polygenic disease caused by impaired insulin secretion and insulin resistance. Genome-wide association studies (GWAS) were expected to resolve a large part of the genetic component of diabetes; yet, the single nucleotide polymorphisms identified by GWAS explain less than 20% of the estimated heritability for T2D. There was subsequently a need to look elsewhere to find disease-causing factors. Mechanisms mediating the interaction between environmental factors and the genome, such as epigenetics, may be of particular importance in the pathogenesis of T2D. Scope of Review: This review summarizes knowledge of the impact of epigenetics on the pathogenesis of T2D in humans. In particular, the review will focus on alterations in DNA methylation in four human tissues of importance for the disease; pancreatic islets, skeletal muscle, adipose tissue, and the liver. Case–control studies and studies examining the impact of non-genetic and genetic risk factors on DNA methylation in humans will be considered. These studies identified epigenetic changes in tissues from subjects with T2D versus non-diabetic controls. They also demonstrate that non-genetic factors associated with T2D such as age, obesity, energy rich diets, physical activity and the intrauterine environment impact the epigenome in humans. Additionally, interactions between genetics and epigenetics seem to influence the pathogenesis of T2D. Conclusions: Overall, previous studies by our group and others support a key role for epigenetics in the growing incidence of T2D. Keywords: Epigenetics, DNA methylation, Type 2 diabetes

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acb9a91dde2ed703af4dea93e95946b7Test